13G Filing: James E. Flynn and Audentes Therapeutics Inc (BOLD)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Deerfield Mgmt 0 1,214,423 0 1,214,423 1,214,423 4.38%
Deerfield Mgmt III 0 889,230 0 889,230 889,230 3.21%
Deerfield Management Company 0 2,103,653 0 2,103,653 2,103,653 7.59%
Deerfield Special Situations Fund 0 514,423 0 514,423 514,423 1.86%
Deerfield Partners 0 308,000 0 308,000 308,000 1.11%
Deerfield International Master Fund 0 392,000 0 392,000 392,000 1.41%
Deerfield Private Design Fund III 0 889,230 0 889,230 889,230 3.21%
James E. Flynn 0 2,103,653 0 2,103,653 2,103,653 7.59%

Page 1 of 18 – SEC Filing

 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 2) *
Audentes Therapeutics, Inc.

(Name of Issuer)
Common Stock, par value $0.00001 per share

(Title of Class of Securities)
05070R104

(CUSIP Number)
April
24, 2017

(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
          o Rule 13d-1(b)
          x Rule 13d-1(c)
          o Rule 13d-1(d)
(Page 1 of 15 Pages)
———-

* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)